NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015.

Slides:

Advertisements

Similar presentations

David M. Pollock Medical College of Georgia Discovery-Academia.

Advertisements

Small Molecule PD and Imaging – Models and Assay Development DCTD Phase 0 Primer, September 5, 2007 Ralph E Parchment, PhD SAIC-Frederick, Inc., NCI-Frederick,

1 NCORP Overview November 2013 NCORP Director Worta McCaskill-Stevens, MD, MS Chief, Community Oncology and Prevention Trials Research Group Division of.

The IndianaCTSI Biorepository is committed to serving the repository needs for CTSI investigators. The core will tailor specimen management to the needs.

Role of the Statistician and the Bioinformatics Scientist in Cancer Clinical Trials Larry Rubinstein, PhD Biometric Research Branch, NCI International.

Influencing Change in Research, Treatment Protocols, and New Drug Development.

Cancer Treatment from the DNA Perspective

Center for Biologics Evaluation and Research FDA Overview Site Visit Carolyn A. Wilson, Ph.D. Associate Director for Research.

Introduction of Cancer Molecular Epidemiology Zuo-Feng Zhang, MD, PhD University of California Los Angeles.

Cancer Clinical Trials:

Cancer Nanotechnology: New Opportunities for Targeted Therapies FDA Public Meeting October 10, 2006 Piotr Grodzinski, Ph.D. Director, Nanotechnology for.

Introduction to Molecular Epidemiology Jan Dorman, PhD University of Pittsburgh School of Nursing

Biomedical research methods. What are biomedical research methods? An integrated approach using chemical, mathematical and computer simulations, in vitro.

ICARE Member Reports ETP seeks to improve incentives and encourage commercial investment in new therapies. (Treatments reach patients only by commercial.

1 The UK Opportunity: what is experimental medicine? UNLOCK YOUR GLOBAL BUSINESS POTENTIAL Pre- clinical development Phase I Phase II Phase III Product.

Howard Fillit, MD Executive Director Improving Animal Trials for Alzheimer’s Disease: Recommendations for Best Practices.

Stress Regulation of Tumor Biology Robert T. Croyle, PhD Director Division of Cancer Control and Population Sciences Concept Presentation NCI Board of.

EVOLVING PUBLIC HEALTH AND HEALTH CARE LANDSCAPE AND OPPORTUNITIES FOR CANCER COMMUNICATION NCI Health Communication and Informatics Research Branch CPCRN.

CALGB Informational Session June 22, 2007 David Hurd, MD Interim Chair Data Audit Committee.

Ensuring the Quality of Genetic Testing ICORD Meeting September 14, 2007 Lisa Kalman, PhD Coordinator, GeT-RM CDC

Critical Path Opportunities for Biologics Products Jesse L. Goodman, M.D. M.P.H. Director Kathryn M. Carbone, M.D. Associate Director for Research Center.

“Critical Path” for Food and Nutrition Science Board November 5, 2004 Alan M. Rulis.

Johns Hopkins Technology Transfer 1 Translational Biomedical Research: Moving Discovery from Academic Centers to the Community Translational Biomedical.

NIH Roadmap for Medical Research and Common Fund Update on Recent Changes Dinah Singer, Ph.D. Director, Division of Cancer Biology June 18, 2008.

Caveats We are interpreting the guidelines along with you We may have some limited additional insight due to participation during the course of planning.

Biorepository Software Selection University of Michigan 31-Aug-2012 Frank Manion, Chief Information Officer Paul McGhee, Lead Business Analyst Cancer Center.

The Need for Organ Site Specific Cancer Research John T Isaacs Chemical Therapeutic Program Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

NCI Review of the Clinical Trials Process 6 th Annual National Forum on Biomedical Imaging in Oncology James H. Doroshow M.D. April 7, 2005 Bethesda, Maryland.

Tissue Bank Challenges Repository and Pathologist View Elizabeth H. Hammond M.D.

U.S. Dept. Agriculture Agricultural Research Service Rob Griesbach Technology Transfer Coordinator

Partnering with Federal Labs: A Panel Discussion FLC Mid-Atlantic Region Annual Meeting October 24, 2007.

SARS Research Resources at NIAID Linda C. Lambert, Ph.D. Program Officer Influenza, SARS, and Related Viral Respiratory Diseases NIAID/NIH/DHHS.

Background: Clinical and Translational Research Centers promote scientific collaborations. The Puerto Rico Clinical and Translational Research Consortium.

Update From FDA: Office of the Commissioner and Center for Drug Evaluation and Research Janet Woodcock, M.D. Acting Deputy Commissioner for Operations.

The Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial Fifth Annual African-American Prostate Cancer Disparity Summit September 24, 2009 Christine.

The Cancer Systems Biology Consortium (CSBC)

Mississippi Comprehensive Cancer Control Plan (2006 ~ 2011) Overview Mina Li, MD (FMG), MS Director, Comprehensive Cancer Control Mississippi Department.

CPTR Overview CPTR 2012 Workshop October 2-4, 2012.

Cancer Centers In Clinical Trials Sandrine Marreaud Head of Medical Department.

Major Components of FDA’s Action Plan for Acrylamide Richard Canady, PhD DABT US Food and Drug Administration Center for Food Safety and Applied Nutrition.

Slide 1 Community Networks to Reduce Cancer Health Disparities Pre-Application Conference May 26, 2004 Bethesda, MD Kenneth C. Chu, PhD Chief, Disparities.

Other Intramural Training Opportunities at NCI Scientific DisciplinesProgram Population-based research, environmental & genetic determinants of cancer.

6/4/20161 Commitment & Efforts Toward Translational Science Subtitle Placeholder.

OMICS International welcomes submissions that are original and technically so as to serve both the developing world and developed countries in the best.

Team Building: Critical Role of Interdisciplinary Research Teams in Translational Research C. Kent Osborne, M.D. Director, Lester and Sue Smith Breast.

Initiating phase 1 clinical trials in pediatric oncology National Cancer Institute Perspective Barry Anderson, MD, PhD Pediatric Section Cancer Therapy.

Dinutuximab (ch14.18) for children with high-risk neuroblastoma

Progress of the SNM Clinical Trials Network Michael Graham, PhD, MD Clinical Trials Network Co-Chair SNM President 1.

Role of the Drug Project Team in Formulating the Initial Development Plan of NCI-IND agents Jeff Moscow, MD IDB, CTEP.

Cancers of the Digestive System November 19, 2007 NCDD Meeting Chair: John M. Carethers, MD Vice Chair: Robert Sandler, MD, MPH.

Integrating Pharmacogenomic Questions Into GCIG Ovarian Cancer Clinical Trials Lori Minasian, MD Chief, Community Oncology and Prevention Trials Research.

CTEP Visiting Physician Externship Coordinator: Igor Espinoza-Delgado, M.D. NCI CTEP Investigational Drug Branch

Massachusetts Cancer Prevention Community Research Network (MCPCRN) CPCRN Atlanta Meeting October 15-16, 2009.

NCI Initiatives to Develop Non-Clinical Models for Pediatric Oncology Malcolm A. Smith, MD, PhD 17 March 2004.

Inflammatory Bowel Diseases November 19, 2007 NCDD Meeting Chair: Daniel K. Podolsky, MD Vice Chair: Eugene B. Chang, MD.

NIAMS Extramural Scientific Planning Retreat 2013 April 4, 2013 Session 1: Strategies for Successful Rare Disease Clinical Trials.

Recent Studies Funded by the Progressive MS Alliance Tim Coetzee, PhD ACTRIMS 2016.

RAS Initiative at the Federally Funded Research and Development Center at Frederick Presented By: Sara S. Hook October 1, 2015.

U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Neurological Disorders and Stroke Big Discoveries, Small.

Division of Cancer Treatment and Diagnosis Presented By: Michael Difilippantonio, Ph.D. October 1, 2015.

University of Virginia Innovation – How to Make Your Grant New and Unique Grant Writing Workshop American Association for Thoracic Surgery David R. Jones.

Clinical Trials.

Telephone    Provider of Global Contract Research Services Accelerating Preclinical Research, Drug Discovery.

Tissue Collection & Banking Facility

Evaluation of NCI Research Resources

The Lifecycle of Pharmaceutical products

OMICS Journals are welcoming Submissions

From Bench to Clinical Applications: Money Talks

Overview of Clinical & Translational Penn

IND Review Process Seoul National University

Presentation transcript:

NCI Division of Cancer Prevention Ongoing Activities at Frederick Facilities Presented By: Lori Minasian, M.D. Robert Shoemaker, Ph.D. October 1, 2015

2 Overview of Mission and Purpose

3 The Division of Cancer Prevention (DCP) conducts and supports research to determine a person's risk of cancer and to find ways to reduce that risk.  DCP funds researchers and collaborative scientific networks, including clinical trials networks  DCP provides scientific support to develop interventions for cancer prevention and markers for the early detection of cancer

4 Major DCP Programs That Use FNLCR Resources Community Research Programs  Current: NCI Community Oncology Research Program (NCORP).  Closed: Community Clinical Oncology Research Program (CCOP) conducted two large breast cancer prevention trials and two large prostate cancer prevention trials that generated specimens. 

5  The Early Detection Research Network (EDRN) is an investigator- initiated infrastructure to support development and validation of early detection biomarkers and markers of progression; foster interaction between academic, clinical and industrial leaders; standardize biomarker validation criteria; develop a quality assurance program; and bring biomarkers to clinical use.  The EDRN has a need for tissue storage and specimen processing for extramural investigators.  Major DCP Programs That Use FNLCR Resources (2)

6 Major DCP Programs That Use FNLCR Resources (3)  PREVENT supports the development of potential cancer prevention agents using mechanism-based assays in vitro and in vivo, as well as defining efficacy, including pharmacodynamics or surrogate endpoint biomarkers of validated, or yet to be studied, chemopreventive agents and vaccines.  The main objectives of these studies are to prioritize and validate potential chemopreventive agents and surrogate endpoints for toxicological/pharmacokinetics/pharmacodynamics evaluation and ultimately for their use in clinical prevention trials. Support is also provided for drug or vaccine synthesis, formulation, and stability studies. 

7 Major DCP Programs That Use FNLCR Resources (4)  The Nutritional Sciences Research Group promotes and supports studies establishing a comprehensive understanding of the precise role of diet and food components in modulating cancer risk and tumor cell behavior. Basic, translational and clinical studies are supported to understand the interplay between nutrition and the microbiome, the underlying mechanisms implicated in cancer prevention, as well as the interplay between genetics, gene expression and dietary intake.

8 Overview of Scientific Work

9 Overview of Scientific Work Biorepositories/ Specimen Storage  Specimen storage and processing are required for several major programs.  Specimen processing storage and access by extramural investigators continues beyond the life of the grant or contract which funded the original study and specimen collection.

10 Overview of Scientific Work Biorepositories/ Specimen Storage Specimen Processing & Distribution  The ability to process the specimens requires seamless collaboration and coordination with the extramural data centers for the identification and processing of the specimens for each individual proposal.  The ability to be flexible in interactions with the investigators who have requested the specimens as each proposal may require thousands of specimens to be processed and distributed to investigators worldwide.  For example, SELECT had 35,533 participants  The processing includes, but is not limited to DNA extraction and plating specimens in different schemas.

11 Overview of Scientific Work Biorepositories/ Specimen Storage Early Detection Research Network  Receiving samples for specimen reference sets, aliquotting them to smaller sizes, maintaining them in freezers, and shipping out to investigators who obtain approval to test their biomarkers.  Sets are used only for pre-validation or validation studies of markers, one of the chief purposes of EDRN.  Currently, the repository is in the process of transferring specimens from an extramural investigator to the FNLCR.

12 Overview of Scientific Work PREVENT Cancer Preclinical Drug Development Program Preclinical Model Development  Genetically engineered mice (GEM) for cancer prevention studies, such as BRCA-driven models of ovarian and mammary cancer. Cancer Immunoprevention  Support for next generation HPV vaccine development, including assays and animal studies.

13 Overview of Scientific Work Nutritional Sciences Research Group  Samples (preclinical and clinical) provided to the transcriptomic laboratory for micro-RNA analyses and initial characterization of the pathways most influenced by food components.